Vascular Closure With a Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study

Sponsor
Kansas City Heart Rhythm Research Foundation (Other)
Overall Status
Recruiting
CT.gov ID
NCT06078735
Collaborator
(none)
110
6
2
14
18.3
1.3

Study Details

Study Description

Brief Summary

The LockeT II study is a single center, prospective randomized study. It is intended to study the effectiveness of using LockeT device to gain hemostasis after venous procedures as compared to Manual Compression (MC). Approximately 110 patients will be enrolled.

Condition or Disease Intervention/Treatment Phase
  • Device: Vascular closure with LockeT device
N/A

Detailed Description

The volume of catheter ablation procedures for the treatment of atrial fibrillation and other arrhythmias are on the rise in the United States and worldwide. Despite decrease in complication rates due to refinement in ablation tools and techniques, achieving vascular hemostasis following large-bore sheath femoral access remains a challenge. Thus, MC remains the current standard of care. However, MC requires up to 8 hours of prolonged bedrest, which is associated with longer length of stay and complications from indwelling catheters.

Another method of vascular closure is the figure-of-eight (FoE) stitch - a subcutaneous suture that has been evaluated to achieve homeostasis following major cardiovascular procedures.

In recent years, invasive, vascular closure devices have become popular. However, results continue to suggest that the risk versus benefit has not been definitively demonstrated. Instead, the LockeT is a new suture retention device designed to closely mimic manual compression by distributing the tension of a FoE stitch over a larger surface area. In such a way, patients can have the benefits of MC without a healthcare professional to stand bedside.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
110 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Patients will be randomized 1:1 to LockeT device or Manual Compression.Patients will be randomized 1:1 to LockeT device or Manual Compression.
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Vascular Closure With Novel Ergonomic External Compression Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study
Actual Study Start Date :
Oct 2, 2023
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: LockeT

These are the patients assigned for LockeT device arm to close the access site wound.

Device: Vascular closure with LockeT device
For subjects that are assigned to the LockeT device arm, the healthcare professional will place the LockeT with suture above the wound to achieve compression instead of manually holding pressure on the sutures. After hemostasis is achieved and prior to ambulation the LockeT will be removed followed by suture removal.

No Intervention: Manual compression

These are the patients assigned for Manual Compression arm to close the access site wound.

Outcome Measures

Primary Outcome Measures

  1. Effectiveness of using the LockeT suture retention device [2 Days]

    Effectiveness of using the LockeT suture retention device to gain hemostasis after venous procedures as compared to standard Manual Compression (MC) will be assessed.

Secondary Outcome Measures

  1. Patient, physician, and nursing staff benefits [2 Days]

    Patient, physician, and nursing staff benefits of the LockeT device will be assessed via LockeT device questionnaire with a scale of 1 to 5, 1 strongly disagree and 5 strongly agree.

  2. Patient discomfort with Locket device [2 Days]

    Pain discomfort will be assessed via Locket device questionnaire with a scale of 1 to 5, 1 strongly disagree and 5 strongly agree.

  3. Incidence of hematoma/ecchymosis [2 Days]

    The incidence of hematoma/ecchymosis post-procedure will be assessed.

  4. Safety of LockeT device [2 Days]

    Safety of LockeT device will be assessed by the incidence of adverse events, including but not limited to: vascular complications, like atrioventricular (AV) fistula, retroperitoneal bleed, surgical exploration of the groin (thrombin injection, open surgery or ligation); need for blood transfusion, defined as a 2 gm post-procedure drop in hemoglobin, or symptoms of anemia,).

  5. Comparison of Manual Compression labor cost and Locket device cost [2 Days]

    Manual Compression labor cost and Locket device cost will be compared

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Must be at least 18 years of age

  • Be able to provide consent

  • Presenting for planned procedures that require percutaneous venous punctures, such as atrial fibrillation radiofrequency ablation, and where the physician utilizes a LockeT device or MC to close the wound.

Exclusion Criteria:
  • Under the age of 18

  • Unable to or unwilling to provide consent

  • Cannot comply with study requirements

  • Not undergoing procedures that require a percutaneous venous puncture or planned access to the left atrium and/or ventricle

  • Subjects whose physician does not use LockeT or MC to close the venous puncture.

  • Patient is currently pregnant, as evidenced by positive urine Beta-HCG. (Urine Beta Human chorionic gonadotropin (HCG) will be checked in all females of the reproductive age group).

  • If the physician detects a formed hematoma prior to venous closure, that patient will be excluded from the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kansas City Heart Rhythm Institute - Roe Clinic Overland Park Kansas United States 66211
2 Overland Park Regional Medical Center Overland Park Kansas United States 66215
3 Centerpoint Medical Center Clinic Independence Missouri United States 64057
4 Centerpoint Medical Center Independence Missouri United States 64057
5 Research Medical Center Clinic Kansas City Missouri United States 64032
6 Research Medical Center Kansas City Missouri United States 64032

Sponsors and Collaborators

  • Kansas City Heart Rhythm Research Foundation

Investigators

  • Principal Investigator: Dhanunjaya Lakkireddy, MD, Kansas City Heart Rhythm Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Kansas City Heart Rhythm Research Foundation
ClinicalTrials.gov Identifier:
NCT06078735
Other Study ID Numbers:
  • KCHRRF_LockeT II_0023
First Posted:
Oct 12, 2023
Last Update Posted:
Oct 12, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 12, 2023